London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From DM,
Investors can now add Hemogenyx Pharmaceuticals to the watch list after it pulled off the near impossible by raising $4.2million at a time when investors have largely gone into hibernation. This feat of resourcefulness, which will fund the initial stages of a first-in-human study of the drug developer's lead asset, HEMO-CAR-T, only tells part of the story. The pedigree of the scientific team backing the efforts of Hemogenyx is impressive.
At the same time, the interest in the next generation of CAR-T – the type of therapy that Hemogenyx is developing – amongst big pharma has seen the likes of AstraZeneca, Johnson & Johnson, Abbvie and Novartis top the billion-dollar threshold in milestone and royalty payments? Upfront payments, usually a good litmus test of 'real' interest from these titans of the world of drugs, have been eye-watering; in some cases up to $100million.
The reason? CAR-T offers something that the healthcare industry rarely comes up with – a curative treatment, showing the world has truly moved on from the era of me-too, once-a-day pills such as statins.
Anyway, before we delve into the nuts and bolts of the Hemogenyx investment case, it is probably worth explaining just what CAR-T therapy is and how it might revolutionise the treatment of cancers such as acute myeloid leukaemia (AML), which is the particular area of interest of this UK biotech
CAR-T, or chimeric antigen receptor T-cell therapy, redefines the battle against the disease by reprogramming the body's own natural defences, called T-cells, to recognise and kill cancer cells. This advanced form of immunotherapy involves extracting T-cells from a patient, genetically engineering them to target cancer cells, and then reintroducing these enhanced cells into the patient's bloodstream.
CAR-T has demonstrated remarkable success in tackling certain blood cancers, offering new avenues for combating previously untreatable cancers. Despite its potential, much of the research is now focused on CAR-T therapy's significant side effects, while broadening its applicability to a wider array of cancers.
Hemogenyx will use the newly raised funds to take HEMO-CAR-T into the clinic to treat AML later this year
The open-label study will test for any potential side effects from treating people with blood-borne diseases and assess how the therapy interacts with the body.
A secondary goal or 'endpoint' will be whether any of the critically ill AML patients chosen for the trial respond to the CAR-T infusion.
Under the strict guidelines laid down by the US Food & Drug Administration, patients will be dosed individually one month apart, recognising people are being administered with a potentially toxic cells.
Hemogenyx hopes to have the results from 'two, or even three patients' in time for the American Society of Hematology conference in early December.
Success at this stage would be a 30% response rate, says Dr Vladislav Sandler, chief executive and co-founder of Hemo
2nd part of article, great to see something positive
work will be carried out by a team from the University of Pennsylvania, led by Professor Nolle Frey, who has headed a number of important CAR-T clinical trials.
The entre was provided by Professor Carl June, the 'father' of CAR-T, and his colleague, Dr Saar Gill, who was involved in the preclinical research on HEMO-CAR-T.
On the university's involvement, Sandler said: 'This isn't a situation where we've paid [UPenn] to carry out the work. They don't work like that. All along it been data driven.'
While no guarantee of success, it provides validation for the science behind the efforts of Hemogenyx.
So expensive is the process of creating individual CAR-T treatments, that cash raised in February may be enough to dose three patients
Hemogenyx will look to further non-dilutive funding to assess a cohort of around 18 AML sufferers, which will take it to the phase II stage of the clinical evaluation.
This is key, as it is the point that big pharma has weighed into the sector with the deals mentioned above.
If all of this suggests that Hemogenyx is a one-trick pony, then that would be misleading.
Before moving into the area of CAR-T, its team together with Eli Lilly, developed a breakthrough that enhances bone marrow and stem cell transplant procedures
The approach focuses on the initial critical stages of eradicating diseased cells and replacing them with healthy ones, using a CDX bi-specific antibody that is both safer and more effective than traditional chemotherapy.
'We decided to do something that other people wouldn't touch at that time,' says Sandler. This has been a theme with all of Hemogenyx's research - attempting the difficult.
As such, the company has created and is a leader in the field of chimeric bait receptors. Put simply, CBRs are designed to attract and catch harmful cells, like cancer cells, by pretending to be something the harmful cells want to attach to.
Once the bad cells latch onto these bait receptors, the immune system can easily find and destroy them.
Its research is being deployed to combat brain cancers such as glioblastoma and neurodegenerative diseases where delivering therapeutics across the blood-brain barrier has long been problematic.
At the same time, it is working on intranasal delivery of CBRs to tackle airborne viral infections, an area of research germane to the civil defence industry and the military.
While Sandler wouldn't be drawn on exactly who he is talking to, there are discussions with parties interested in helping develop the viral infections defense deployment, the CEO confirmed.
'We are talking to institutions and agencies,' Sandler says. 'There is a lot of interest and we are moving these conversations along.
The Ice Age-like big freeze across the small-cap market in the UK means none of company's potential has been captured in the current share price, which values Hemogenyx at a bargain basement £21million
Isn’t it a repeat of the one that Haywain posted (via JHFH)? Either way it’s still great publicity via the daily mail that will be seen by many people. Should make the price increase tomorrow too
Thank you to all who have posted this. Come on HEMO lets get you the credit you deserve.
An RNS to support this article would be just what the scientist ordered. Good luck hemo as we approach trial news.
It is the same article but posted through multiple media outlets - "This is money" also posted the same article.
An article isn't going to lift the price of hemo not now not in this market i think that's wishful thinking.
I read somewhere that when comparing avacta to hemo there was no comparison at all from a risk reward perspective. The article went on to say avacta is in a league of its own and the ceo has confirmed last week they have the holy grail in cancer treatment yet shares haven't budged. Its all about sales. Looks like avacta have to wait 2 years for sales which feels like forever but at least they are funded now for at least 2 years.
What is the cash position here at hemo looking like and when are they expecting sales?
JWBellamy perhaps you could answer as you seem to know everything about hemo and are trying to cross ramp it on other bulletin boards like your post on avacta today
Aldebaran, as someone who's followed Avacta for several years, including the CEO's often "contradictory or goalpost moving proclamations" (an observation that many of Avacta's LTH's would no doubt agree with), rest assured that - if they did have the "holy grail of cancer care" - they'd almost certainly have been bought into by Big Pharma, and the SP would not be languishing where it now is. No offence but the fact that you place so much credence on the fact that "the CEO's told us" (so it must be true) suggests rose-coloured specs to me. A few biopsies aside, let's see more 'proper' AVCT "holy-grail" efficacy data (as opposed to wat has primarily been 'safety and tolerability' info to date) before believing the hype.
The one thing I agree with you on? You cannot compare AVCT with Hemo.
Bellamy is not to be trusted. He is a known troll on the Avacta board or an alias.
Fwiw I hold both investments and have high hopes for both.
Why would it be worth anything that YOU own both pedroL?
I think most people Invested here have never heard of you...FWIW I'm invested here and also highly invested in magic beans...anyone wanna buys magic beans?? Top quality, low dollar...
Just showing I'm not partizan either way Barber.
Pretty aggressive response but you're probably another TW clone.
TW? Never heard of it.
Sounds more like you're Partizan both ways...
Just sounds like BS on top of BS.
Barbershop, how much for five?
Cross-ramping / deramping helps neither board. Both companies have their respective merits.